Lunes, 31 de agosto de 2009

GRACE, TRITON-TIMI 38, TRIANA o BEATIFUL son algunos de los estudios que despertaron más expectación en la jornada del lunes del ESC Congress de Barcelona'09. Ya puedes consultar en webcast todas las sesiones del día.

Presentación	Ponente	Tema
An outline of the new guidelines.	D Poldermans (Rotterdam, NL)	Peripheral circulation/Stroke
Perioperative beta-blockers.	B Iung (Paris Cedex 18, FR)	Peripheral circulation/Stroke
Perioperative anti-platelet therapy after coronary artery stenting.	E Eeckhout (Lausanne, CH)	Peripheral circulation/Stroke
Electrical repolarisation changes in young athletes; what is abnormal?	D Corrado (Padova, IT)	Cardiac rehabilitation and training
Asymptomatic ventricular extrasystoles in athletes: benign or potentially fatal?	A Biffi (Rome, IT)	Cardiac rehabilitation and training
Impact of ethnicity on electrocardiogram and cardiac dimensions in young athletes.	S Sharma (London, GB)	Cardiac rehabilitation and training
Evaluation of the right ventricle in highly trained young athletes.	A La Gerche (Leuven, BE)	Cardiac rehabilitation and training
GRACE: Discussant.	C W Hamm (Bad Nauheim, DE)	Ischaemia / ACS / infarction
Primary Angioplasty versus Fibrinolysis in the Very Elderly. The TRIANA Study.	H Bueno (Madrid, ES)	Ischaemia / ACS / infarction
TRIANA: Discussant.	D Dudek (Krakow, PL)	Ischaemia / ACS / infarction
Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock. The PRAGUE-7 Study.	P Widimsky (Praha 10, CZ)	Interventional cardiology
PRAGUE-7: Discussant.	A Lafont (Paris Cedex 15, FR)	Interventional cardiology
Randomized Trial of 3-Limus Agent-Eluting Stents With Biodegradable or Permanent Polymer Coating. ISAR-TEST-4 study.	J Mehilli (Munich, DE)	Interventional cardiology
ISAR-TEST-4: Discussant.	AD Kugelmass (Detroit, US)	Interventional cardiology
How to cool the burning plaque.	V Fuster (New York, US)	Epidemiology & prevention
Risk factors have no boundaries.	D A Wood (London, GB)	Epidemiology & prevention
Total risk assessment: principles and practice.	M-R Taskinen (Helsinki, FI)	Epidemiology & prevention
Modern diabetic management; it's not just glucose.	C Berne (Uppsala, SE)	Epidemiology & prevention
The final piece of the puzzle; comprehensive risk reduction.	G De Backer (Ghent, BE)	Epidemiology & prevention
ESC/ESH hypertension guidelines What's new?	G Mancia (Monza, IT)	Hypertension
Metabolic risk management.	A J Manolis (Athens, GR)	Hypertension
Blood pressure management.	S E Kjeldsen (Oslo, NO)	Hypertension
Causes of cardiovascular disease in Asia and Europe: one and the same?	M Woodward (Sydney, AU)	Epidemiology & prevention
The differences in cardiovascular risk factors and treatment goal achievement between the Asian and the European: results of the Lipid Treatment Assessment Project 2 (L-TAP 2).	F-T Chiang (Taipei, TW)	Epidemiology & prevention
Global alert and prevention of infectious heart diseases.	A Matsumori (Kyoto, JP)	Epidemiology & prevention
Behavioural skills training for health care providers.	N Houston-Miller (Palo Alto, US)	Epidemiology & prevention
Motivational interviewing - is it effective in cardiovascular prevention?	PM Davidson (Sydney, AU)	Epidemiology & prevention
Behavioural change - it's all in the family.	C S Jennings (London, GB)	Epidemiology & prevention
Can we change society?	J Tuomilehto (Helsinki, FI)	Epidemiology & prevention
Clinical, biomarker and gene profile: do they really help?	G Pasterkamp (Utrecht, NL)	Nuclear cardiology, CMR & CT
Vascular profile: carotid intima-media thickness, brachial reactivity, ABI index - what role?	J Fernandes E Fernandes (Lisbon, PT)	Nuclear cardiology, CMR & CT
Plaque profile: atheroma morphology and biology - clinically useful?	J Narula (Orange, US)	Nuclear cardiology, CMR & CT
Myocardial profile: morphology and function - good for prediction?	M Vannan (Columbus, US)	Nuclear cardiology, CMR & CT
Impact of exercise on cardiac and vascular cell biology.	V Adams (Leipzig, DE)	Heart failure / LV dysfunction
Exercise and heart failure prevention: epidemiological evidence.	P Giannuzzi (Veruno, IT)	Heart failure / LV dysfunction
Exercise training in heart failure; which practical modality?	V Conraads (Edegem, BE)	Heart failure / LV dysfunction
Lessons from HF-ACTION.	C O'Connor (Durham, US)	Heart failure / LV dysfunction
Hypertrophic cardiomyopathy.	L Monserrat (A Coruna, ES)	Myocardial-Pericardial disease
Dilated cardiomyopathy.	E Arbustini (Pavia, IT)	Myocardial-Pericardial disease
Characterisation and functional role of endothelial progenitor cells in the arterial wall.	S Dimmeler (Frankfurt, DE)	Cardiovascular system (patho)physiology
Role of endogenous cardiac progenitor cell for cardiac revascularisation.	A H P Linke (Leipzig, DE)	Cardiovascular system (patho)physiology
Role of stem cells in plaque growth and destabilisation.	J F Martin (London, GB)	Cardiovascular system (patho)physiology
Olive oil, berries and chocolate.	M De Lorgeril (La Tronche, FR)	Epidemiology & prevention
Hop, skip or jump.	P Doherty (York, GB)	Epidemiology & prevention
I did it my way.	S Sharma (London, GB)	Epidemiology & prevention
The Risk of Cardiovascular Event for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial.	M O'Donoghue (Boston, US)	Ischaemia / ACS / infarction
TRITON-TIMI 38: Discussant.	K Huber (Vienna, AT)	Ischaemia / ACS / infarction
Effect of rosiglitazone on coronary events in the RECORD study.	J J V McMurray (Glasgow, GB)	Ischaemia / ACS / infarction
RECORD: Discussant.	B Charbonnel (Nantes, FR)	Ischaemia / ACS / infarction
Effect of ivabradine on cardiovascular outcomes in patients with stable CAD and LV dysfunction with limiting angina: a subgroup analysis of the BEAUTIFUL trial.	R Ferrari (Ferrara, IT)	Ischaemia / ACS / infarction
BEAUTIFUL: Discussant.	G Heusch (Essen, DE)	Ischaemia / ACS / infarction
Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older. JUPITER.	R Glynn (Boston, US)	Epidemiology & prevention
JUPITER: Discussant.	P G Steg (Paris Cedex 18, FR)	Epidemiology & prevention
International impact of atherothrombotic vascular disease and events: 3-year data from the REACH Registry.	M Alberts (Chicago, US)	Peripheral circulation/Stroke
REACH: Discussant.	N Danchin (Paris, FR)	Peripheral circulation/Stroke
Copenhagen City Heart. Discussant.	V Fuster (New York, US)	Epidemiology & prevention
Focal adhesion kinase regulates load-induced PGC-1a expression and mitochondrial biogenesis in mice left ventricle.	T Tornatore (Campinas, BR)	Cardiovascular system (patho)physiology
Myocardial ischemia/reperfusion injury is mediated by leukocytic TLR2 and reduced by systemic administration of a novel anti-TLR2 antibody.	F Arslan (Utrecht, NL)	Cardiac cellular biology
Exosomes are the active cardioprotective component in MSC secretion.	D De Kleijn (Utrecht, NL)	Cardiovascular system (patho)physiology
Chronic, low dose epoetin-? treatment following PCI significantly improves left ventricular ejection fraction in ischemic heart failure.	M W Bergmann (Hamburg, DE)	Heart failure / LV dysfunction
Approach to diagnosis and classification.	A Cohen-Solal (Paris, FR)	Heart failure / LV dysfunction
Pharmacological treatment for systolic dysfunction.	G Sinagra (Trieste, IT)	Heart failure / LV dysfunction
Devices and surgery for low ejection fraction heart failure.	D J van Veldhuisen (Groningen, NL)	Heart failure / LV dysfunction
Treatment for preserved ejection fraction heart failure.	P Ponikowski (Wroclaw, PL)	Heart failure / LV dysfunction
Cardiac resynchronisation therapy in patients with mild heart failure.	C Linde (Stockholm, SE)	Arrhythmias / Pacing / Resynchronisation
Cardiac resynchronisation therapy in heart failure patients with atrial fibrillation.	A Auricchio (Lugano, CH)	Arrhythmias / Pacing / Resynchronisation
Left-ventricular based pacing for bradycardia.	E Simantirakis (Heraklion, GR)	Arrhythmias / Pacing / Resynchronisation
Barriers to implementation.	I M Graham (Dublin, IE)	Epidemiology & prevention
Political alliances and engagement - prerequisites for success.	L Ryden (Stockholm, SE), S Logstrup (Brussels, BE)	Epidemiology & prevention
Factors influencing physician and patient behaviour.	C Albus (Cologne (Koeln), DE)	Epidemiology & prevention
A national plan for cardiovascular disease prevention.	C Erol (Ankara, TR)	Epidemiology & prevention
The 'Call for Action': putting strategy into practice.	G De Backer (Ghent, BE)	Epidemiology & prevention

Cardiología hoy | Blog

Guías clínicas

Agenda SEC

CardioPODCAST

Cursos SEC

Másteres y Posgrados

Formación SEC 2025

CardioTV

Lunes, 31 de agosto de 2009

Actualidad

Revista Española de Cardiología

REC: Interventional Cardiology

REC: CardioClinics

Socios estratégicos